NASDAQ:AMGN - Amgen Stock Price, Forecast & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 5.1% and is now trading at $208.88. View which stocks have been mosted impacted by Coronavirus.

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amgen.

Amgen, Inc. (NASDAQ:AMGN) released its earnings results on Thursday, January, 30th. The medical research company reported $3.64 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $3.47 by $0.17. The medical research company earned $6.20 billion during the quarter, compared to the consensus estimate of $6.04 billion. Amgen had a net margin of 33.57% and a return on equity of 85.52%. The firm's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.42 earnings per share. View Amgen's earnings history.

Amgen declared a quarterly dividend on Wednesday, March 4th. Stockholders of record on Monday, May 18th will be paid a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date of this dividend is Friday, May 15th. View Amgen's dividend history.

Amgen updated its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $14.85-$15.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.10. The company issued revenue guidance of $25.0-$25.6 billion, compared to the consensus revenue estimate of $25.41 billion.

26 analysts have issued 1-year price objectives for Amgen's stock. Their forecasts range from $185.00 to $277.00. On average, they anticipate Amgen's stock price to reach $238.70 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View analysts' price targets for Amgen.

Press coverage about AMGN stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amgen earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAmgen.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Repligen (RGEN) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), Home Depot (HD) and Gilead Sciences (GILD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cullinan Associates Inc. (0.01%), McGuire Investment Group LLC (0.00%), Thomasville National Bank (0.00%), Birch Capital Management LLC (0.00%), Park National Corp OH (0.00%) and M&R Capital Management Inc. (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., Thomasville National Bank, Fulcrum Equity Management, Park National Corp OH, McGuire Investment Group LLC, and Private Asset Management Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Birch Capital Management LLC, Orrstown Financial Services Inc., and M&R Capital Management Inc.. View insider buying and selling activity for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $208.88.

Amgen has a market capitalization of $123.20 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe. View additional information about Amgen.

The official website for Amgen is http://www.amgen.com/.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]